【レポートの概要（一部）】
1. Report Overview
1.1 Non-Small Cell Lung Cancer (NSCLC) Overview
1.2 Why You Should Read this Report
1.3 How this Report Delivers
1.4 Main Questions Answered by this Report
1.5 Who is this Report for?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQ)
1.8 Some Associated Reports
1.9 About Visiongain
2. Introduction to NSCLC and its Treatment
2.1 Lung Cancer is the Most Common Cancer, and NSCLC Accounts for 85%-90% of All Cases
2.2 The Three Main Histological Sub-Types of NSCLC
2.3 Genetic Mutations Allow for Targeted Therapies
2.4 Staging of NSCLC
2.5 Treatment Protocols by Stage
2.5.1 Stage 1 or 2
2.5.2 Stage 3
2.5.3 Stage 4: First Line-Therapy
2.5.3.1 Standard Chemotherapy Used to be the Only Treatment Option
2.5.3.2 Newer Therapies offers Improved Treatment Outcomes
2.5.3.3 Summary of First-Line Therapy Options: Un-Met Need in Squamous Patient Population
2.5.4 Maintenance Therapy
2.5.5 Second-Line and Third-Line Therapy
3. Leading NSCLC Drugs, 2015-2025
3.1 Alimta (pemetrexed) by Eli Lilly – The Leading NSCLC Therapy
3.1.1 Mechanism of Action
3.1.2 Three out of its Four FDA-Approved Indications are for NSCLC
3.1.3 Patent Expiries
3.1.3.1 ‘Method-Of-Use’ Vitamin Dosage Regimen Patent – Alimta’s Saviour from Generic Competition?
3.1.4 NICE Rejects Alimta for Maintenance Therapy
3.1.5 Total Alimta Revenues, 2010-2014
3.1.6 Alimta for NSCLC, 2014
3.1.7 Alimta for NSCLC Forecast, 2015-2025
3.2 Avastin (bevacizumab) – Roche’s Cancer Behemoth is a Leading Presence in NSCLC
3.2.1 Mechanism of Action
3.2.2 Multiple Approved Indications, but NSCLC was one of the First
3.2.3 Growing Discontent with Avastin in NSCLC – Is it Cost-Effective?
3.2.4 Total Avastin Revenues, 2010-2014
3.2.5 Avastin for NSCLC Forecast, 2015-2025
3.3 Tarceva (erlotinib) by Roche
3.3.1 Mechanism of Action
3.3.2 Three of Four Indications are for NSCLC
3.3.3 NICE Changes Mind on Tarceva – and then Changes it Back Again
3.3.4 Total Tarceva Revenues, 2010-2014
3.3.5 Tarceva for NSCLC Forecast, 2015-2025
3.4 Iressa (gefitinib) by AstraZeneca
3.4.1 Iressa Finally Returns to the Crucial US Market after Four Year Departure
3.4.2 Iressa NSCLC Revenues, 2010-2014
3.4.3 Iressa for NSCLC Forecast, 2015-2025
3.5 Gilotrif (afatinib) by Boehringer Ingelheim
3.5.1 Newcomer to the Market Rounds out the Trio of Currently Approved EGFR Inhibitors
3.5.2 Gilotrif Displays Significant Survival Benefit over Tarceva in Squamous Setting
3.5.3 Gilotrif for NSCLC Forecast, 2015-2025
3.6 Xalkori (crizotinib) by Pfizer
3.6.1 Mechanism of Action
3.6.2 The First Approved ALK Inhibitor
3.6.3 Co-Promotion with Merck KGaA, and has Treated Over 8,000 Patients
3.6.4 Xalkori NSCLC Revenues, 2012-2014
3.6.5 Xalkori for NSCLC Forecast, 2015-2025
3.7 Abraxane (paclitaxel Protein-Bound) by Celgene
3.7.1 Mechanism of Action
3.7.2 Relatively Recent Approval for NSCLC Indication
3.7.3 Finally Approved for NSCLC in the EU
3.7.4 Total Abraxane Revenues, 2010-2014
3.7.5 Abraxane for NSCLC Forecast, 2015-2025
3.8 Taxotere (docetaxel) by Sanofi
3.8.1 Mechanism of Action and Approved Indications
3.8.2 Sanofi Unable to Prevent Generics, Despite Appeal
3.8.3 Total Taxotere Revenues, 2010-2014
3.8.4 Taxotere for NSCLC Forecast, 2015-2025
3.9 Cyramza (ramucirumab) by Eli Lilly
3.9.1 Mechanism of Action
3.9.2 Many Approvals in Quick Succession
3.9.3 Cyramza for NSCLC Forecast, 2015-2025
3.10 Gemzar (gemcitabine) by Eli Lilly
3.11 Zykadia (ceritinib) by Novartis
3.11.1 Mechanism of Action and Recent Approval
3.11.2 Zykadia for NSCLC Forecast, 2015-2025
3.12 Opdivo (nivolumab) by Bristol-Myers Squibb
3.12.1 Mechanism of Action – Works With the Immune System to Fight Cancers
3.12.2 Swift Approvals through FDA Priority Review Programmes
3.12.3 Good News and Bad News for NSCLC from CheckMate Trials
3.12.4 Opdivo for NSCLC Forecast, 2015-2025
4. NSCLC R&D Pipeline, 2015-2025
4.1 Alecensa (alectinib) by Roche
4.1.1 Japan Becomes First Country to Approve and Launch Alectinib
4.1.2 Roche is Inching Closer Towards the All-Important US Approval
4.1.3 Four Ongoing Clinical Trials involving Alectinib in NSCLC
4.1.4 Japanese Revenues and Future Outlook
4.2 Vargatef (nintedanib) by Boehringer Ingelheim
4.2.1 EU Becomes First Region to Approve Vargatef
4.2.2 NICE has a Change of Heart on Vargatef
4.2.3 Ongoing Clinical Trials Involving Vargatef in NSCLC
4.3 AZD9291 by AstraZeneca
4.3.1 Regulatory Filings in the US and EU, Expected Times for Filings in Japan and China
4.3.2 Collaboration with Roche to Develop Companion Diagnostic
4.3.3 Positive Preliminary Results Presented at ASCO 2015
4.3.4 Ongoing Clinical Trials Involving AZD9291 in NSCLC
4.4 Rociletinib (CO-1686) by Clovis Oncology
4.4.1 In a Race to Approval Against AZD9291
4.4.2 Results So Far Have not Distinguished it Enough from Main Rival
4.4.3 Four Ongoing Clinical Trials Involving Rociletinib in NSCLC
4.5 Keytruda (pembrolizumab) by Merck (MSD)
4.5.1 Has Been Approved for Melanoma, NSCLC is one of the Next Major Targets
4.5.2 Ongoing Clinical Trials Involving Keytruda in NSCLC
4.6 Ganetespib (STA-9090) by Synta Pharmaceuticals
4.6.1 Ganetespib Mechanism of Action
4.6.2 Three Ongoing Clinical Trials Involving Ganetespib in NSCLC
4.7 Halaven (eribulin) by Eisai
4.7.1 Halaven Mechanism of Action
4.7.2 Clinical Trials Involving Halaven in NSCLC
4.8 Necitumumab by Eli Lilly
4.8.1 Phase 3 Results Show Modest Benefits and Worrying Adverse Event Profile
4.8.2 Eli Lilly has Filed for Approval in US and EU, and Verdict is Likely to be Positive, Despite Reservations
4.8.3 Ongoing Clinical Trials Involving Necitumumab in NSCLC
4.9 Atezolizumab (MPDL3280A) by Roche
4.9.1 Mechanism of Action
4.9.2 Atezolizumab Doubles Likelihood of Survival in Certain Subset of Patients
4.9.3 Six Ongoing Clinical Trials Involving Atezolizumab in NSCLC
5. Global NSCLC Market, 2015-2025
5.1 The Global NSCLC Market Forecast, 2015-2025
5.2 What Factors will Drive Growth in the Global NSCLC Market?
5.3 Growing Ageing Population
5.4 The Identification of Biomarkers for Targeted Therapies
5.5 Dynamic and Lucrative Sector with Strong Pipeline
5.6 Satisfying the Large Un-Met Need that is Treatment for Squamous Patients
5.7 What Factors will Restrain Growth in the Global NSCLC Market?
5.8 Patent Expiries and Generic Erosion will be the Main Detriment to the Market
5.9 New Therapies That Reportedly Offer Only Modest Benefits Over Existing Treatments
5.10 Declining Healthcare Budgets lead to Cost Pressures, and Resistance to Therapies is another Issue
5.11 SWOT Analysis of the Global NSCLC Market
6. Leading Therapeutic Segments and National Markets within the Global NSCLC Market
6.1 Therapeutic Composition of the Market in 2015 Compared to 2025
6.1.1 Therapeutic Segments Forecast, 2015-2025
6.1.2 Chemotherapy Segment Forecast, 2015-2025
6.1.3 EGFR and ALK Inhibitors Segment Forecast, 2015-2025
6.1.4 VEGF / VEGFR Inhibitors Segment Forecast, 2015-2025
6.1.5 Immunotherapy Segment Forecast, 2015-2025
6.2 Leading National Markets for NSCLC
6.2.1 Regional Composition of the Global Market in 2015, Compared to 2025
6.2.2 Leading Regional Markets for NSCLC Forecast, 2015-2025
6.2.3 US NSCLC Market, 2015-2025
6.2.3.1 Experiencing Some Changes, but Will Retain Dominance Throughout Forecast Period
6.2.3.2 US NSCLC Market Forecast, 2015-2025
6.2.4 EU5 NSCLC Market, 2015-2025
6.2.4.1 German NSCLC Market: Leader in EU, but Facing Big Reforms
6.2.4.2 German NSCLC Market Forecast, 2015-2025
6.2.4.3 French NSCLC Market: Strong National Healthcare System, Despite Economic Woes
6.2.4.4 French NSCLC Market Forecast, 2015-2025
6.2.4.5 Italian NSCLC Market
6.2.4.6 Italian NSCLC Market Forecast, 2015-2025
6.2.4.7 UK NSCLC Market: Pricing is a Key Issue, Providing Restraints to Revenues
6.2.4.8 UK NSCLC Market Forecast, 2015-2025
6.2.4.9 Spanish NSCLC Market
6.2.4.10 Spanish NSCLC Market Forecast, 2015-2025
6.2.5 Japanese NSCLC Market
6.2.5.1 Expansion of the Generics Market is a Key Factor
6.2.5.2 Japanese NSCLC Market Forecast, 2015-2025
6.2.6 BRIC NSCLC Market, 2015-2025
6.2.6.1 China NSCLC Market: Rapid Growth Will Make it one of the Major Global Players
6.2.6.2 China NSCLC Market Forecast, 2015-2025
6.2.6.3 Brazilian NSCLC Market: Taken Great Strides Forward with Healthcare
6.2.6.4 Brazilian NSCLC Market Forecast, 2015-2025
6.2.6.5 Russian NSCLC Market: Punches Below its Weight
6.2.6.6 Russian NSCLC Market Forecast, 2015-2025
6.2.6.7 Indian NSCLC Market: Generics are King
6.2.6.8 Indian NSCLC Market Forecast, 2015-2025
7. Research Interview
7.1 Interview with Novartis
7.1.1 On the Need for More than one ALK Inhibitor on the Market
7.1.2 Main Trends and Opportunities for NSCLC
7.1.3 The Present and the Future
8. Conclusions from Our Research and Analysis
8.1 How Will Revenues Change over the Forecast Period?
8.2 How will the Therapeutic Composition of the Market Change over the Forecast Period?
8.3 How Will the National Composition of the Global Market Change Over the Forecast Period?
8.4 Concluding Remarks
【レポート販売概要】
■ タイトル：非小細胞肺がん（NSCLC）治療薬の世界市場：市場、企業、研究開発展望■ 英文：Non-Small Cell Lung Cancer Drugs: Market, Companies and R&D Outlook 2015-2025
■ 発行日：2015年10月
■ 調査会社：visiongain
■ 商品コード：VGAIN5112511
■ 調査対象地域：グローバル
- 世界の固化防止剤市場2015The Global Anti-Caking Agents Industry 2015 Market Research Report is a professional and in-depth study on the current state of the Anti-Caking Agents industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Anti-Caking Agents market analysis is provided for the international markets including development t …
- 化学品物流の世界市場2015-2019About chemical logistics Logistics deals with the procurement, planning, and implementation of activities in the forward and reverse logistics chain of an organization. The chemical industry uses logistics for the complete management of the way resources are acquired, stored, and moved to different end-user locations. The use of logistics helps the chemical industry to have a continual supply of h …
- アメリカ教育産業における人口知能（AI）市場2017-2021About Artificial Intelligence Artificial intelligence analyzes huge data sets at granular levels. These data can potentially help both students and mentors who are involved in the developmental and personalized education process. Irrespective of the subject, these solutions have capabilities to create personalized learning profiles for students. The technology helps educators to develop optimized …
- 世界の凝固検査（Coagulation Testing）市場：課題、新技術、競争環境“New Frontiers in Point-of-Care/POC Coagulation Testing: Business Challenges, Emerging Technologies, Competitive Landscape” is Venture Planning Group’s new report, which provides comprehensive analysis of the POC coagulation testing market, including its dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging opportunities for in …
- Occidental Petroleum Corporation：石油・ガスバリューチェーン分析レポート2013Occidental Petroleum Corporation Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "Occidental Petroleum Corporation" Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “Occidental Petroleum Corporation”. The report provides key information relating to oil and gas assets of the company along with its operations acr …
- マイクロソフトのフェイスブックサイト分析（Microsoft Reliance on Facebook for Social Media: Analysis of Multiple Microsoft FB Sites）Over 700 billion minutes a month are spent on Facebook, 20 million applications are installed per day and over 250 million people interact with Facebook from outside the official website on a monthly basis, across 2 million websites. Over 350 million people access Facebook via their mobile phone. Fourty-eight percent of young people say they now get their news through Facebook. Meanwhile, in just …
- 月経カップの世界市場2019-2023Global Menstrual Cups Market: About this market Technavio’s menstrual cups market analysis considers sales from both reusable menstrual cups and disposable menstrual cups. Our analysis also considers the sales of menstrual cups in Asia, Europe, North America, and ROW. In 2018, the reusable menstrual cup chocolate segment had a significant market share, and this trend is expected to continue over t …
- 分路リアクトルの世界市場予測（～2022年）：油入式分路リアクトル、空心式分路リアクトル、可変リアクトル、固定リアクトルThe global shunt reactor market is projected to grow at a CAGR of 4.56% from 2017 to 2022, and is projected to reach a market size of USD 3.19 Billion by 2022. This growth can be attributed to the increasing demand for electricity, upgradation of the aging technology in the developed nations, augmentation and modernization of the transmission and distribution network. Also, addition of high transm …
- 世界の輸配送管理システム市場（2014-2018）About Transportation Management System A transportation management system (TMS) is mainly used to plan freight movements. TMS helps customers plan and execute transportation across their supply chain. It offers a number of important tools, such as strategic planning and optimization, freight consolidation, and freight audit and payment, which helps to maximize the efficiency and reduce freight cos …
- LCDパネル用バックライトユニットの世界市場About LCD Backlight Unit An LCD backlight unit forms a significant component of an LCD display device. It provides illumination for the projection of an image on the screen. LCDs do not produce light; therefore, backlight units act as a light source for displaying the image. Three major types of backlight units used for illuminating LCDs are cold-cathode fluorescent lamp (CCFL), white-edge light-e …
- バスバーの世界市場2016-2020About Busbar A busbar is a metallic strip or bar capable of conducting electricity. It is an essential component of the electrical power grid that enables the grid to conduct electricity while reducing power loss simultaneously. The materials used for busbar construction and its dimensional specifications determine the maximum current it can safely conduct. Low power rating busbars are used in ele …
- 凍結乾燥（フリーズドライ）食品の世界市場2019-2023108 Pages, November 2018 About this market Factors such as the high demand for convenience food, rising global urban population, and high purchasing power in emerging countries are identified as key trends that will gain traction in the market. A considerable shift in the lifestyle and diet is resulting in an increase demand for freeze-dried food products. Technavio’s analysts have predicted that …
- テレプレゼンス・ロボットの世界市場2016-2020About the Telepresence Robots Market A telepresence robot is a computer-driven robot that consists of a video camera and screen to have a view of either side. It is a remote-controlled ambulatory device equipped with a display to enable video chat and conference. Its basic equipment includes a microphone, a video camera, and a wireless transmitter that enables the robot to communicate via an Inter …
- 口紅の世界市場2015-2019About Lipsticks The Americas were the largest market, followed by Asia Pacific (APAC), Europe, and the Middle East and Africa (MEA). The US registered the highest demand for lipstick in 2014, followed by China. The easy availability of counterfeit products is one of the major issues faced by manufacturers. Nude-colored and organic lipsticks are trending in the market. Technavio’s analysts forecast …
- グローバル通信キャリアのクラウドサービス市場The Cloud has moved beyond simply computing to encompass communications, applications, content, and commerce. Approximately 90% of global Internet users already depend on the Cloud, either directly through consumer services, or indirectly through their service provider’s reliance upon various Cloud as a Service solutions on a business-to-business (B2B). While the Cloud ecosystem has enjoyed much s …
